Safety and immunogenicity of a paediatric presentation of an influenza vaccine

• Published in: Archives of disease in childhood Vol. 83; no. 6; pp. 488 - 491
• Main Authors: Gonzalez, M, Pirez, M C, Ward, E, Dibarboure, H, García, A, Picolet, H
• Format: Journal Article
• Language: English
• Published: London BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health 01.12.2000; BMJ; BMJ Publishing Group LTD; BMJ Group
• Subjects: Adults; Age; Antibodies, Viral - biosynthesis; Antigens; Babies; Biological and medical sciences; Child, Preschool; Chronic illnesses; Data Analysis; Ear diseases; Epidemics; Epidemiology. Vaccinations; Female; General and Specialist Paediatrics; General aspects; Hemagglutination Inhibition Tests; HIV; Human immunodeficiency virus; Humans; Immunogenicity; Infant; Infections; Infectious diseases; Influenza; Influenza A virus - immunology; Influenza B virus - immunology; influenza vaccine; Influenza Vaccines - adverse effects; Influenza Vaccines - immunology; Influenza, Human - prevention & control; Male; Medical sciences; Mothers; safety; Syringes; Tropical medicine; Vaccination - adverse effects; Vaccines; Vaccines, Inactivated - adverse effects; Vaccines, Inactivated - immunology; Viruses; Young Children; Human; Infection; Prevention; Immunogenicity; Viral disease; Treatment efficiency; Influenza; Vaccination; Secondary effect; Vaccine; Safety; Child
• ISSN: 0003-9888; 1468-2044
• DOI: 10.1136/adc.83.6.488

BACKGROUND Flu vaccination in otherwise healthy infants and young children is important to prevent severe disease, as well as to control epidemic spread of influenza infection. AIMS To examine the safety and immunogenicity of a paediatric presentation of a purified, inactivated, triton split influenza vaccine. METHODS Two doses of the vaccine, provided in prefilled syringes of 0.25 ml, were administered, one month apart, to 67 children under 3 years of age. RESULTS Nine cases of immediate reaction to vaccination (macules/papules) were observed after the second injection only. During the study period, 9% of children experienced at least one delayed local reaction, and 28% of children presented at least one systemic reaction. Almost all reactions were mild and transient. Immunogenicity results surpassed the European Community recommendations for a 0.50 ml dose of vaccine in adults. CONCLUSION This paediatric formulation of inactivated flu vaccine appears safe and immunogenic in children from 6 months to 3 years of age; the convenient presentation in a prefilled syringe of 0.25 ml volume will facilitate administration of the dose recommended for young children.